Low-level physical activity predictors among adults living with HIV in Ethiopia’s southern region, focusing on work, transportation, and recreation domains: unmatched case-control study

Table 2 Bivariable analysis, on HIV/AIDS-associated factors and LLPA, cases-controls, PLWHs, southern Ethiopia, 2023

Determinants	Low Level Physical Activity(LLPA)		COR (95% CI)	P-value
	Cases (n = 262)	Controls (n = 371)
	No	No
ART status
ART-naive	84	127	1
ART exposed	178	244	1.10(0.79–1.54)	0.06***
Type of ART regimen
Non-in either of the two Therapy (Rx)^a	84	127	1
1st line	176	236	1.13(0.81–1.58)	0.49
2nd line	2	8	0.38(0.08–1.82)	0.23***
1st line ART regimen
AZT-3TC-NVP	36	43	1
AZT-3TC-EFV	18	17	1.27(0.57–2.81)	0.56
TDF-3TC-EFV	102	137	0.89(0.53–1.48)	0.65
TDF + 3TC + NVP	20	35	0.68(0.34–1.38)	0.29
ABC + 3TC + EFV	86	4	NC
NA /Not applicable	36	135	0.76(0.45–1.28)	0.30
Duration since diagnosed with HIV
< 1 year	33	55	1
1–4 Years	208	275	1.26(0.79–2.01)	0.33
5–9 Years	21	41	0.85(0.43–1.69)	0.65
Duration since on ART
< 1 year	55	16
1–4 Years	48	113	0.12(0.06–0.24)	0.000**
5–9 Years	43	95	0.13(0.07–0.26)	0.000**
Functional status
Ambulatory	73	99
Working	189	272	0.94(0.66–1.34)	0.74
WHO staging
< III stage	215	274
≥ III stage	42	92	0.58(0.39–0.87)	0.009**
OI other than TB
No	232	307
Yes	30	64	0.62(0.39–0.99)	0.04*
Recent TB status
No	223	318	1
Yes	39	53	1.05(0.67–1.64)	0.83
CD4-levels cells mm3
< 350	37	50	1
350–500	64	84	1.03(0.60–1.76)	0.92
≥500	161	237	0.92(0.57–1.47)	0.72
Viral RNA levels > = 1500 copies/ml
No	252	358	1
Yes	10	13	0.92(0.40–2.12)	0.84

Notes *significant at P < 0.05 **Significant at P < 0.01 ***Significant at P < 0.25
Predictors: ART status, Type of ART regimen,1st line ART regimen, OI other than TB, Functional status, WHO staging, Viral RNA levels > = 1500 copies per ml, CD4-levels cells mm3, Duration since on ART, Duration since diagnosed with HIV
Outcome: cases with low level physical activity (LLPA), control without LLPA
Abbreviations: Rx–Therapy; HIV, human immunodeficiency virus; PLWH; people living with HIV, ART, antiretroviral therapy; 1st line regimen; 2nd line regimen; OI, opportunistic infections; TB, tuberculosis; WHO, world health organizations; RNA, Ribonucleic Acid; ml, milliliter; mm3, cubic millimeter; COR, crude odd ratio; AOR, Adjusted odd ratio

ISSN: 2052-1847